Companies › Tcelltech
2 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TX103 Anti-B7-H3 chimeric antigen receptor T-cell (CAR-T cell) therapy | B7H3 | Phase 1 | High-grade Glioma; Solid Tumors | Jun 2027 |
| DIT309 CAR-T cell therapy | – | Phase 1 | Osteosarcoma | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06482905 | TX103 | Phase 1 | High-grade Glioma | Oncology | Jun 2027 |
| NCT07052383 | DIT309 | Phase 1 | Osteosarcoma | Oncology | Oct 2027 |
| NCT07231081 | TX103 | Phase 1 | Solid Tumors | Oncology | Dec 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.